Evidence map›Paper›PMID 32511873›Full record

ArticleCancer medicine2020

Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non-small cell lung cancer.

Nima Aghdam, Mary McGunigal, Haijun Wang, Michael C Repka, Mihriye Mete, Stephen Fernandez, Chiranjeev Dash, Waddah B Al-Refaie, Keith R Unger

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Epidemiology and survival factors for sarcoma patients in minority populations: a SEER-retrospective study.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Nima AghdamDepartment of Radiation Medicine, MedStar-Georgetown Hospital, Washington, DC, USA.
Mary McGunigalDepartment of Radiation Medicine, MedStar-Georgetown Hospital, Washington, DC, USA.ORCID 0000-0002-6264-144X
Haijun WangMedStar Health Research Institute, Hyattsville, MD, USA.
Michael C RepkaNYU Winthrop Hospital, New York, NY, USA.
Mihriye MeteMedStar Health Research Institute, Hyattsville, MD, USA.
Stephen FernandezMedStar Health Research Institute, Hyattsville, MD, USA.
Chiranjeev DashGeorgetown Lombardi Comprehensive Cancer Center, Office of Minority Health & Health Disparities Research, Washington, DC, USA.ORCID 0000-0002-3314-8461
Waddah B Al-RefaieMedStar-Georgetown Surgical Outcomes Research Center, Washington, DC, USA.ORCID 0000-0002-2590-5522
Keith R UngerDepartment of Radiation Medicine, MedStar-Georgetown Hospital, Washington, DC, USA.
MedStar Georgetown University Hospital · USMedStar Health · USGeorgetown University · USOffice of Minority Health · USWinthrop-University Hospital · US

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
NCATS NIH HHS UL1 TR001409
6 · The paper itself

Abstract

backgroundEthnicity and insurance status have been shown to impact odds of presenting with metastatic cancer, however, the interaction of these two predictors is not well understood. We evaluate the difference in odds of presenting with metastatic disease in minorities compared to white patients despite access to the same insurance across three common cancer types.

methodsUsing the National Cancer Database, a multilevel logistic regression model that estimated the odds of metastatic disease was fit, adjusting for covariates including year of diagnosis, ethnicity, insurance, income, and region. We included adults diagnosed with metastatic prostate, non-small cell lung cancer (NSCLC), and breast cancer from 2004 to 2015.

resultsThe study cohort consisted of 1 191 241 prostate cancer (PCa), 1 310 986 breast cancer (BCa), and 1 183 029 NSCLC patients. Private insurance was the most protective factor against metastatic presentation. Odds of presenting with metastatic disease were 0.190 [95% CI, 0.182-0.198], 0.616 [95% CI, 0.602-0.630], and 0.270 [95% CI, 0.260-0.279] for PCa, NSCLC, and BCa compared to uninsured patients, respectively. Private insurance provided the most significant benefit to non-Hispanic White PCa patients with 81% reduction in odds of metastatic presentation and conferred the least benefit to African-American NSCLC patients at 30.4% reduction in odds of metastatic presentation.

conclusionsInsurance status provided the single most protective effect against metastatic presentation. This benefit varied for minorities despite similar insurance. Reducing metastatic disease presentation rates requires addressing social barriers to care independent of insurance.

Indexed as

Breast NeoplasmsCarcinoma, Non-Small-Cell LungFemaleHumansInsurance CoverageLung NeoplasmsMaleNeoplasm MetastasisProstatic Neoplasmsbreastinsurance and ethnicity interactionlungmetastatic cancerprostate

Identifiers

PMID32511873
PMCPMC7402826
OpenAlexW3033147528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.